author-photo

Torben Plesner

University of Southern Denmark

229

Papers

7464

Citations

Citation Trend

Filter By

Papers (166) Sort By

Journal Conference Others

Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: Frailty subgroup analysis of MAIA

2022
Show All
- Source
- Cite
- Save
Citations (0)
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (1)
Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab

2021 Journal of Clinical Medicine
- Torben Plesner
Show All
- Source
- Cite
- Save
Citations (0)
Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1.

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (4)
MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
Rapid and Sustained Reduction of Immunosuppressive T-Cells and Focusing of the T-Cell Repertoire in t(11;14) Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Daratumumab and Dexamethasone

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)